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1. Introduction
Neurofibromatosis (NF) is a rare genetic-hereditary syndrome with autosomal 
dominant transmission and complete penetrance yet variable clinical expression. It 
is precisely this genotypically defined but phenotypically variable behavior of the 
NF which is of particular interest as it is able to influence not only the timeliness of 
clinical diagnosis but also the prognosis of the disease. Indeed, in most cases clinical 
diagnosis is early (within the first 3 years after birth), but in particular forms with 
a low phenotypic expression, especially in the mosaic forms of mild neurofibro-
matosis type 2 (NF2), it can be later, with clinical manifestation of the syndromic 
features in early adulthood [1, 2].
The known syndromic features of NF, although still framed in the con-
text of rare diseases, differ in their incidence and clinical manifestations. 
Neurofibromatosis type 1 (NF1) is the most frequent, with an incidence of 1 indi-
vidual per 2500/3500 live births, without significant gender differences and at least 
50% related to de novo mutations [3]. Neurofibromatosis type 2 has an incidence of 
new cases/year equal to 1 individual for every 25,000/30,000 live births, correlating 
in 80% of cases to de novo mutations, and a prevalence of around 1/100,000 which 
has, over the past 20 years, been increasing hand in hand with the introduction of 
new and more sophisticated diagnostic methods [2].
It is well documented that NF1 is characterized by the presence of an autosomal 
dominant mutation of a gene on chromosome 17 in position q11, which codes for 
a protein known as neurofibromin, which acts as a tumor suppressor in the pro-
proliferative pathway RAS/MEK-MAPK. The total absence of functional protein 
therefore cancels the inhibitory activity on the RAS proto-oncogene with conse-
quent hyperactivation of the transduction mechanism and the pro-proliferative and 
pro-mitotic cellular response.
Different mutations have been described on the gene which codes for neurofi-
bromin [4]. In recent years, questions have been raised as to whether the presence 
of one particular type of mutation rather than another might affect the prognosis of 
the disease. A study published in Lancet in August 2014 [1] highlighted the possible 
prognostic role of multiple genomic microdeletions in the context of the entire 
gene, the presence of which seems to be associated with a more severe phenotypic 
expression, characterized by the appearance of plexiform neurofibromas at an early 
age, a significant reduction in IQ , multiple craniofacial anomalies, and a higher risk 
of malignant degeneration of peripheral neurofibromatous lesions.
On the other hand, the mutation associated with NF2 is autosomal dominant of a 
gene located on chromosome 22 in position q12.2, which codes for a protein known 
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as merlin or schwannomin which seems to have a role, not yet fully clarified, as a 
tumor suppressor in the contact inhibition mechanism of the proliferative stimulus. 
The alterations of schwannomin seem to be phenotypically expressed exclusively in 
Schwann cells [5] which would justify, from the molecular point of view, the almost 
total absence of other neoplastic entities in patients with NF2 or NF3.
Neurofibromatosis type 3, better known as Schwannomatosis, can be considered 
a variant of NF2 characterized, however, by the total absence of vestibular schwan-
nomas and neurofibromas and by the lower presence of tumors of the central 
nervous system. NF3 is, rather, characterized by the presence of multiple schwan-
nomas along the course of the peripheral nerves [6].
It has therefore been understood over time that while those gene mutations 
related to the various NF conditions have complete penetrance, there is consider-
able variability in terms of the phenotypic expression of the disease, not only 
between the three syndromic forms of NF but also within each type of neurofibro-
matosis. Hence the interest of this book, which aims to offer the reader a perspective 
on neurofibromatosis that goes beyond academic descriptions of what is already 
known with respect to the different clinical manifestations of NF, instead focuses 
interest on specific clinical disease patterns, related neurocognitive aspects, and 
therapeutic developments that in recent years have been emerging in the manage-
ment of the various types of neurofibromatosis, especially in the direction of new 
targeted molecular therapies.
As is well documented, the diagnostic criteria for NF1 have, since 1987, been 
defined by the National Institutes of Health [7], which includes a variable combina-
tion of the following manifestations: abnormal pigmentation of epithelial and mucous 
membranes (cafè-au-lait macules, axillary and inguinal freckling, Lisch nodules 
of the iris); multiple peripheral neurofibromas; bone abnormalities and deformi-
ties (osteopenia, scoliosis, sphenoid wing dysplasia, congenital tibial dysplasia); 
cardiovascular anomalies and malformations (congenital heart disease, vasculopathy, 
and hypertension); and neurocognitive deficits.
Even more variable are the clinical manifestations associated with NF2, whose 
most commonly used diagnostic criteria are the “Manchester diagnostic criteria” [8]. 
Such criteria include multiple central nervous system tumors (intracranial meningiomas, 
43–58%); intramedullary spinal cord tumors (ependymomas in more than 75%); 
benign tumors of the cranial nerves (vestibular schwannoma, 90–95%) that may or 
may not be bilateral; peripheral nerve schwannomas; ophthalmological changes; dermal-
epidermal skin tumors of varying natures; and moreover, a familiar history of NF2.
Following clinical examination and ultrasound diagnostics for skin and 
subcutaneous lesions, the gold standard in the diagnosis of neurofibromatosis is 
magnetic resonance imaging with gadolinium of the brain and spinal cord. It has 
been observed that in patients with NF1, it is not uncommon to locate focal hypoin-
tense lesion areas in T1-weighted and slightly hyperintense lesions in T2-weighted 
sequences, the so-called unidentified bright objects (UBOs), the actual nature of 
which is still discussed in the literature, although their presence can correlate with 
cognitive dysfunction [9]. A previous study by Griffiths et al. speculated that they 
could correspond to areas of subclinical glial proliferation, having hypothesized an 
association between their early diagnosis in resonance and the relative risk (around 
80%) of subsequent development of central tumors of the glial series at between 5 
and 10 years of age [10].
Malignant forms of neurofibromas and, more rarely, peripheral schwannomas 
degenerated into sarcomas are termed as “malignant peripheral nerve sheath 
tumors” (MPNSTs) and are more frequently associated with the malignant evolu-
tion of plexiform neurofibromas more commonly in the third decade of life and 
with poor prognosis [11, 12].
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The treatment of the syndrome is mainly surgical with the removal of both 
central and peripheral lesions causing functional or evolving damage during follow-
up diagnostics. The support that intraoperative neurophysiological monitoring can 
provide to the surgical resection technique is of fundamental importance, not only 
for saving the nerve but also in preventing the onset of neuropathic pain. Much 
more invasive is the surgical resection of MPNSTs, which can sometimes involve 
amputation or disarticulation to ensure surgical radicalism, followed by adjuvant 
radiotherapy.
Ultimately, while surgery is still considered the first approach to neurofibroma-
tosis, interest in medical therapeutics for this syndrome has grown considerably in 
recent years, and numerous clinical trials are still ongoing, as will be explained in 
detail in the chapters of the book.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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